SEC For	m 4																		
FORM 4 UNITED				STAT	STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
1. Name and Address of Reporting Person [*] Brennan Kevin M. (Last) (First) (Middle) 828 WINTER STREET					2. Issuer Name and Ticker or Trading Symbol Xilio Therapeutics, Inc. [XLO] 3. Date of Earliest Transaction (Month/Day/Year) 08/16/2023								Relationship of Reporting Person(s) to Issuer teck all applicable) Director 10% Owner X Officer (give title Other (specify below) below) SVP, FINANCE AND ACCOUNTING						
SUITE 3 (Street)	SUITE 300				4. If Amendment, Date of Original Filed (Month/Day/Year) 5. Indiv Line) X														
(City)	(S		(Zip)			Chec satisf	k this box y the affirr	to ind native	Cate that a trar	nsaction was r tions of Rule 1	nade pursua 10b5-1(c). Se	ee Instructio	on 10.		plan th	nat is intended	d to		
Date				. Transac	tion	ar) in	CURITIES AC 2A. Deemed Execution Date, if any (Month/Day/Yea		3. 4. Secur Transaction Dispose Code (Instr. 5)		of, or Beneficia ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amou Securitie Beneficia Owned F	nt of 6. C s For ally (D) ollowing (I) (n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	r Price	Transact	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)			
		-	Fable II - Do (e						uired, Dis s, options,				Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Co	4. Transaction Code (Instr.		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Co	de	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							
Stock Option (right to buy)	\$2.785	08/16/2023		A			25,000		(1)	08/15/2033	Common Stock	25,000	\$0	25,00	0	D			

Explanation of Responses:

1. The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date.

<u>/s/ Chris Frankenfield,</u>	00/1
Attorney-in-Fact	<u>08/1</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

/18/2023